Welcome to MOAlifeplus

Research Performance

R&D center

Research Results - Patents

Patents

Through innovative research, we have various patents and are developing unique technologies and products based on these. These research patents play an important role in strengthening the company's competitiveness and continuously leading the industry.

Technology	Domestic		Overseas		Total			Remarks
Technology	Registration	Application	Registration	Application	Registration	Application	Sum	Remarks
HumaMAX	16	1	15	1	31	2	33	Holding various patents for uses based on γ-PGA functionality
MucoMAX	8	1	32	9	40	10	50	Holding core and use patents related to surface expression technology of probiotics
-	1	4	-	-	1	4	5	-
Total	25	6	47	10	72	16	88	- Patents: 88 (72 registered, 16 applications) - Domestic Patents: 31 (25 registered, 6 applications) - Overseas Patents: 57 (47 registered, 10 applications)
Total	31		57		72	16	88

Platform Technology with Global IP Portfolio

Moalifeplus employs a strategic IP portfolio approach, consistently filing and registering core patents for its platform technologies and applications. The company holds patents both domestically and in key international markets.To date, Moalifeplus has filed and registered a total of 88 patents, comprising 31 domestic and 56 international patents. This includes 33 patents related to HumaMAX technology, 50 associated with MucoMAX technology, and 5 covering other innovations.

Platform	Category	Patent Number	Description	Patent Status
MucoMax®	Cervical Precancer	KR 10-1471043	Stable constant high expression cervical cancer therapeutic vaccine vector and recombinant lactic acid bacteria transformed therewith	Registered in Korea / USA and 15 other countries
MucoMax®	Cervical Precancer	US 7871816	Vaccine vectors for human papillomavirus and microorganisms transformed by them	Registered in USA
MucoMax®	Muscular dystrophy	KR 10-0857861	A vector for surface expression of a fusion protein of Myo-2 peptide polymer and myostatin and a microorganism transformed with the vector	Registered in Korea / USA and 2 other countries
MucoMax®	Muscular dystrophy	KR 10-0872042	Cell surface expression vector expressing myostatin and microorganism transformed by said vector	Registered in Korea
MucoMax®	Lactic acid bacteria surface display technology	KR 10-0972843	Novel Constitutive High-Expression Promoter and Its Applications	Registered in Korea / USA and 2 other countries
MucoMax®	Lactic acid bacteria surface display technology	KR 10-1564084	Constitutive high-expression vector containing the repE mutant gene	Registered in Korea, USA, and 1 other country
MucoMax®	Lactic acid bacteria surface display technology	KR 10-2077703	A surface expression vector utilizing poly-gamma-glutamic acid synthesis genes derived from Bacillus strains and a method for microbial surface expression of proteins using this vector	Registered in Korea and 1 other country
MucoMax®	Lactic acid bacteria surface display technology	KR 10-2594583	Constitutive high-expression surface expression vector using the promoter of galactose mutarotase gene derived from lactobacillus casei and its use	Registered in Korea and 3 other countries
MucoMax®	Lactic acid bacteria surface display technology	KR 10-2604524	A vector for simultaneous surface expression of two target proteins using two types of promoters derived from Lactobacillus casei and a method for microbial surface expression of proteins using the same	Registered in Korea and 1 other country
HumaMax®	Antiviral	KR 10-0873179	Use of poly-gamma-glutamic acid in the treatment of cervical dysplasia	Registered in Korea, USA, and 2 other countries
HumaMax®	Antiviral	KR 10-1765600	Use of poly-gamma-glutamic acid in the treatment of cervical dysplasia	Registered in Korea and USA
HumaMax®	Antiviral	KR 10-2538216	A pharmaceutical composition containing poly-gamma-glutamic acid as an active ingredient for the prevention, mitigation, or treatment of coronavirus (SARS-CoV-2) infectious disease.	Registered in Korea
HumaMax®	Anti-allergy	KR 10-0992551	Composition for preventing or treating asthma or allergic diseases containing poly-gamma-glutamic acid	Registered in Korea
HumaMax®	Anti-allergy	KR 10-2496383	Composition for improving atopic skin symptoms containing poly-gamma-glutamic acid	Registered in Korea and 1 other country
HumaMax®	Immunostimulant	KR 10-1342641	Immunoadjuvant composition containing poly-gamma-glutamic acid-quinoic acid nanoparticles	Registered in Korea and 1 other country
HumaMax®	Immunostimulant	KR 10-0517114	Immunoadjuvant composition containing poly-gamma-glutamic acid	Registered in Korea and 3 other countries
HumaMax®	ETC	KR 10-1054808	Composition for improving blood cholesterol content containing poly-gamma-glutamic acid	Registered in Korea
HumaMax®	ETC	KR 10-0582120	Hyaluronidase inhibitor containing poly-gamma-glutamic acid as an active ingredient	Registered in Korea and USA
HumaMax®	ETC	KR 10-1006976	Method for producing poly-gamma-glutamic acid hydrogel	Registered in Korea
HumaMax®	ETC	KR 10-2091587	Cosmetic composition for improving wrinkles containing gamma oligopeptide or its salt	Registered in Korea
HumaMax®	ETC	KR 10-2440573	Prebiotic composition containing poly-gamma-glutamic acid	Registered in Korea

Research Results - Papers

Research Article

As a research-driven company, we have consistently published scientific papers since our inception. To date, we have produced 115 publications, including 111 in basic research and 4 in clinical studies, demonstrating our commitment to scientific advancement.

HumaMAX

45 research papers, 2 clinical papers

MucoMAX

11 research papers, 2 clinical papers

ETC

55 research papers

Key papers

- Anti-Obesity Effect and Signaling Mechanism of Potassium Poly-g-Glutamate Produced by Bacillus subtilis Chungkookjang in High-Fat Diet-Induced Obese Mice, Nutrients 2024, 16, 809

- A New Method of Myostatin Inhibition in Mice via Oral Administration of Lactobacillus casei Expressing Modified Myostatin Protein, BLS-M22. Int. J. Mol. Sci. 2022 Aug 13;23(16):9059.

- A phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3. J. Gynecol. Oncol. 2019 Nov;30(6):e88.

- Oral Administration of Poly-Gamma-Glutamic Acid Significantly Enhances the Antitumor Effect of HPV16 E7-Expressing Lactobacillus casei in a TC-1 Mouse Model. J Microbiol. Biotechnol. 2019 Sep 28;29(9):1444-1452.

- Short-term clinical and immunologic effects of poly-gamma-glutamic acid (γ-PGA) in women with cervical intraepithelial neoplasia 1 (CIN 1): A multicenter, randomized, double blind, phase II trial. PLoS One. 2019 Jun 20;14(6):e0217745.

- Inactivated enterovirus 71 with poly-γ-glutamic acid/Chitosan nano particles (PC NPs) induces high cellular and humoral immune responses in BALB/c mice. Arch Virol. 2018 Aug;163(8):2073-2083.

- Poly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccine. Sci Rep. 2017 Mar 21;7:44839.

- Mucosal vaccination of conserved sM2, HA2 and cholera toxin subunit A1 (CTA1) fusion protein with poly gamma-glutamate/chitosan nanoparticles (PC NPs) induces protection against divergent influenza subtypes. Vet. Microbiol. 2017 Mar;201:240-251.

- Prebiotic Effects of Poly-Gamma-Glutamate on Bacterial Flora in Murine Gut. J. Microbiol. Biotechnol. 2017 Feb 28;27(2):412-415.

- Intranasal administration of poly-gamma glutamate induced antiviral activity and protective immune responses against H1N1 influenza A virus infection. Virol. J. 2015 Oct 6;12:160.

- A single-center, randomized double-blind placebo-controlled study evaluating the effects of poly-gamma-glutamate on human NK cell activity after an 8-week oral administration in healthy volunteers, Evid. Based Complement Alternat. Med. 2013:2013:635960